Germany supports global development of innovative antibiotics
The German Federal Ministry of Education and Research (BMBF) is continuing to support antibiotic research. Recently the BMBF announced a further EUR 50 million in funding for the Global Antibiotic Research and Development Partnership (GARDP).
The partnership is dedicated to developing treatments for bacterial diseases which have acquired anti-microbial resistance (AMR) or cannot be treated with currently available antibiotics. Another GARDP objective is to guarantee sustainable, fair and affordable access to newly-developed antibiotics. German Minister for Education and Research Bettina Stark-Watzinger explained the significance of the GARDP’s work when the latest grant was announced.
“Multi-resistant bacteria pose an increasing danger to people worldwide. Even bacterial infections that have previously been easy to treat can now become life-threatening because many antibiotics are no-longer effective against these pathogens,” said Stark-Watzinger. “That is why I am pleased the BMBF is providing an additional EUR 50 million to support the research and development (R&D) of urgently-needed, innovative antibiotics. Germany therefore continues to remain a powerful and reliable partner in the fight against multi-resistant bacteria,” she continued.
Founded as a non-profit project of the World Health Organization (WHO) and the Drugs for Neglected Diseases Initiative (DNDi) in 2016, GARDP is based in Geneva. Germany, through the BMBF, has provided a total of EUR 61.7 million since 2018.
HEALTH MADE IN GERMANY is the place to learn more about the country’s support of international R&D for innovative drugs. The export initiative for the German healthcare industry monitors closely the leadership role Germany has taken promoting the work of GARDP and similar organizations.
- Recommend this page:
- Print view